Evidence map›Paper›PMID 26317066›Full record

ArticleCurrent transplantation reports2015

New Tools in Experimental Cellular Therapy for the Treatment of Liver Diseases.

Jennifer R Ferrer, Attasit Chokechanachaisakul, Jason A Wertheim

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current transplantation reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Cell therapy in chronic liver disease.Current opinion in gastroenterology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jennifer R FerrerDepartment of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA ; Department of Chemistry, Northwestern University, Evanston, IL 60201, USA ; Chemistry of Life Processes Institute, Northwestern University, Evanston, IL 60201, USA ; International Institute for Nanotechnology, Northwestern University, Evanston, IL 60201, USA ; Simpson Querrey Institute for BioNanotechnology in Medicine, Northwestern University, Chicago, IL 60611, USA.
Attasit ChokechanachaisakulDepartment of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA ; Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, 676 St. Clair St. Suite 1900, Chicago, IL 60611, USA.
Jason A WertheimDepartment of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA ; Chemistry of Life Processes Institute, Northwestern University, Evanston, IL 60201, USA ; International Institute for Nanotechnology, Northwestern University, Evanston, IL 60201, USA ; Simpson Querrey Institute for BioNanotechnology in Medicine, Northwestern University, Chicago, IL 60611, USA ; Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, 676 St. Clair St. Suite 1900, Chicago, IL 60611, USA ; Department of Surgery, Jesse Brown VA Medical Center, Chicago, IL 60612, USA ; Department of Biomedical Engineering, Northwestern University, Evanston, IL 60201, USA.
Northwestern University · US

Funding

Mentoring For Success: Developing Fundamental Skills For Biomedical ResearchR25GM079300 · NIGMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MCGEE, RICHARD · 2007 to 2020
$6.6M
Chemistry of Life Processes Predoctoral Training ProgramT32GM105538 · NIGMS · NORTHWESTERN UNIVERSITY · PI KELLEHER, NEIL L · 2013 to 2022
$2.7M
Optimization and control of hepatocyte activity via biofunctional modificationK08DK101757 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WERTHEIM, JASON A · 2014 to 2018
$777k
MAP KINASE REGULATION OF INSULIN TRANSCRIPTIONF32DK010175 · NIDDK · UNIVERSITY OF TEXAS SW MED CTR/DALLAS · PI GIBSON, TARA B · 2001 to 2003
$127k
NIDDK NIH HHS F32 DK010175NIDDK NIH HHS K08 DK101757NIGMS NIH HHS R25 GM079300NIGMS NIH HHS T32 GM105538
6 · The paper itself

Abstract

The current standard of care for end stage liver disease is orthotopic liver transplantation (OLT). Through improvement in surgical techniques, immunosuppression, and general medical care, liver transplantation has become an effective treatment over the course of the last half-century. Unfortunately, due to the limited availability of donor organs, there is a finite limit to the number of patients who will benefit from this therapy. This review will discuss current research in experimental cellular therapies for acute, chronic, and metabolic liver failure that may be appropriate when liver transplantation is not an immediate option.

Indexed as

Alternative cell sourcesCellular therapyHepatocyte transplantationStem cells

Identifiers

PMID26317066
PMCPMC4547556
OpenAlexW2083881183

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.